Association of the ABCB1 3435C > T polymorphism with antiemetic efficacy of 5-hydroxytryptamine type 3 antagonists

Babaoglu M., Bayar B., Aynacioglu A., Kerb R., Abali H., Celik I., ...Daha Fazla

CLINICAL PHARMACOLOGY & THERAPEUTICS, cilt.78, sa.6, ss.619-626, 2005 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 78 Sayı: 6
  • Basım Tarihi: 2005
  • Doi Numarası: 10.1016/j.clpt.2005.08.015
  • Dergi Adı: CLINICAL PHARMACOLOGY & THERAPEUTICS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.619-626
  • Hacettepe Üniversitesi Adresli: Evet

Özet

Background: Resistance to antiemetic treatment with 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists is still a major problem resulting in patient discomfort and poor compliance to chemotherapy. We hypothesized that clinical resistance to 5-HT3 antagonists is associated with the single-nucleotide polymorphism (3435C > T) in the gene that codes for the drug efflux transporter adenosine triphosphate-binding cassette subfamily B member 1 (A-BCB1).